Seaport and Hemab file for IPOs Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 13 April, 2026

AI has gone from buzzword to pipeline strategy — but are the results a mixed bag? We're talking to the researchers in the thick of it about what's moving the needle, what's stalling out and what comes next. Join us for a free virtual program, then continue the conversation at an in-person-only fireside and happy hour in Boston. Choose your pass.

presented by CNS-3D Brain Organoids Pre­dict Clin­i­cal Seizure Li­a­bil­i­ty, New Study Da­ta

news Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial Updated: Seaport and Hemab file for IPOs, as Kailera prices Strong early data prompts GSK to plan five Phase 3 studies for gynecological cancer ADC

Apr 28 12:30 pm ET Connection ≠ continuity: Rethinking long-term evidence in the age of tokenization sponsored by PicnicHealth Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher

The R&D 15 is John Carroll’s annual reckoning with where biopharma’s biggest players are really investing — and where they’re not. This year he’s back at the table with some of the industry’s top research chiefs for a frank, one-hour conversation on the trends shaping drug development in 2026 and beyond. Join us.

ENDPOINTS PHARMA FDA rejects Replimune cancer therapy, saying company didn't resolve trial doubts Bayer pharma executive predicts US-Europe price spreads will narrow Plan for remade CDC vaccine panel adds focus on vaccine safety, matching Kennedy’s push

in case you missed it 1. A ‘cure’ for five blood disease patients suggests Chinese genetic medicine can compete globally 2. Biotech VCs ramp up checks on new bets after years of focusing on existing portfolios 3. Peer Review Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim 4. News Briefing Vivatides raises Series A for R&D; Wegovy drops cold chain in EU; Gilead picks up $45M Kymera option 5. China-based CAR-T company Oricell raises $40M more as it looks to go public 6. Switzerland Aims to Finalize US Tariff Accord by the End of July